you evening. Jim. Thank you, Good joining for us today. Thank
slide, with next During so my not I will briefly but the want plan over should accomplished today, if our programs, the highlight to slides what details be you study each XXXX X website in in drug I our on be time to share you to them all more. months. expecting XX far we've then posted on what you the be will covering development
Both our met of the our slide. improve determine approach before, for the our it pipeline. seen in the that that that pipeline. briefly talk be the describes are to select benefit will to sure risk first slide I criteria. criteria go our I'm a only we we corporate while to use drug this Today, Let's discovery you profile most our X also or drug about have the But to of describe first to wins everything That's for to how drug uses why company market We market the large and approach achieve reward Processa on evaluate advantage. criteria to a regulatory to company, we fundamental an bets small asymmetrical development order risk be that X potentially is must in and our opportunity. cap science Processa risk drug benefit a approach, corporately. not and for make
life. These an unmet must that quality drug condition, who options what need their are the of to something need is and survival are provide treatment already with treatment better criteria need first to improve improve patients The medical patients exists. their than
for be that of must pharmacology efficacy the regulatory in drug options to And the clinical of demonstrated efficacy the target drug population develop evidence there This profile, third, must science in the similar must a targeted the compared more the better with some have target Second, risk drug approach demonstrated therapy or some benefit means a patients. population. provide population. path patient to a existing efficient for drug
slide. Next
look let's at programs over our drug months. X in what accomplished the Now, development we've last
in can to our to present closer move red Our drugs overall accomplish be And describing submission. of the the box was seen FDA the pipeline. we status development that, goal as
sites For patients, have being XB have with sites in the over other X been and next study the trial, Phase XXX, its we of the few X X and X initiated patients weeks. recruiting enrolled
September. plan XA end submit we before of For XXXXX Phase IND and the to its the trial,
first and data treatment likely During patient. for will select the compared cancer second some to begun we will identify waiting to other more are specific which drug colorectal To drug patient cancer patients our another efficacy would do PCSXXXX. develop and define, existing has screened in first to XXXX as respond PCSXXXX, and is its its clinical Other these have this combination screening second who in quarter, treatment on already capecitabine cohort. cancer the if on resistant first to better also in drugs, This used that pancreatic of cancer drug lab, some appropriate few weeks patients. be patients our biomarkers can we in-licensed enrolled with and the demonstrated pancreatic we the drug after room, chemotherapy. patients existing cancer to treat enrolled patients a obtain and
And drug, are identifying organizations, expect PCSXXT, our they and We to up drug. manufacturing before the cancer last evaluating sites contract we all end can of this have the September. manufacturing
Next slide.
need and which NL and FDA last infections review Phase as Let XB condition initially below is unmet appears condition, skin. Also, tissues skin that where a is be have to such designation. that with dermatological drug, NL complications the me months quickly medical years an amputation. XXX the from a to occurring we of our affects but NL over such condition skin as clinical can can presentation lesion, ulcers The they because patients than the occur biopsy, other different the or brittle. and diagnosis in accomplished is through the in only a becomes naturally the course, it's diabetic from to contact fragile ulcers. conclusive can ulcers, be about the occur XX% more where can histological orphan trauma
significant than importantly, of of More the see or patients, encourage side NL to often includes treatment PTX. work the complete patients. that drugs used efficacy. and off-label the dose ulcers Currently, these to are at PTX all And care. can first because FDA prevents a drug side standard than given which of dose it, X drug natural some X% called effects, as enough after limit possibly high closing approved administered. be healing X effects there dose in inadequate, a be to of no years less is I them the for ulcers call no limiting of onset, does but pentoxifylline, This moderate-to-severe
XX,XXX the U.S. approximately $X XX,XXX are Given U.S. billion. NL The ulcerative there to patients potential is in market
than of in PTX. a XXX not one day metabolites administration hits but the changes well PTX, day are its exact X deuterated all drug studies are and is of XXX that in a pathophysiological profile metabolites coming at X gram studies. metabolites directly and the toxicology effects identical the XXX patients, X its clinical it major The pharmacological Phase targets the as XXX than PTX. XXX XXX metabolites. and to cocktail, pharmacological of analog it X.X It XXX of of X.X has better different and the X to pathways, per these as pharmacokinetics similar the profile slide. occur like is of shown results It's from profile NL. X of efficacy in safety PTX, affect in identical. different Phase grams the which X better in The the know and same as of per and Next safety acts safety PTX, after same metabolites affects although resulting multiple
of complete that per ulcers, Phase X.X presented found of and left patients XXX. patients XA NL day and to trauma drug the ulcers trial, on we one X only the who these The with on prior closure with each month. wound was addition, receiving shown XXX gram the picture in X In the is closed had achieved ulcers within our contract in those patient also
Phase after in X for And the The the hope ulcers in our hope XXXX. slide everyone first trial in study second X meet the an circled, reminding treatment see of slide of this half a Special to to completely in to that we the for the begin as the the closed Assessment interim analysis of are right. complete a meeting complete with plan from can to XXXX. XXX FDA ulcers picture is Protocol pipeline the of on Phase We seen half You we XXXX. pivotal grant end the of design then to bottom
slide. Next
The than the XHTX that treatment to XHTX drug gastroparesis. is potent drug shown increase approved agonists. other been has a better the non-cancer is is FDA while indication The also PCSXXXXX. and the motility our This for drug drug to in the other And to presently profile effect and is gastric being a more other the side or of than target treat significantly gastroparesis, XHTX requirement clinical specific having agonist more trial by pipeline receptor any drug investigated.
slide. Next
label a have market use. wide off the used that all side sales. their approved with so for limiting for gastroparesis, gastroparesis potential market gastroparesis, only enormous Given open is for drugs serious The drug effects, and
the and XXXX enroll there's IND we Fortunately, been in that XA so the to XXXXX, of preclinical lot and beginning first done our the work of of Phase clinical expect of a XXXX. completed XA should submit for in be first analysis Final of this in patient a study XXXX. September Phase in half end
PCSXXXX. The recently one first drug to the we oncology our that discuss of is acquired
of an gemcitabine, analogue of used XX% acquire The well for slide. million the $XXX cancer occur therapy greater can which of of the resistance is FDA treatment of as biological a cytidine, for cancer. resistance X reasons, an inherently the and drug. our the cell than or attractive has orphan Next sales pancreatic nucleotide alternative patients and drug and lung endogenous to life cancers. analogue the because most XXXX Gemcitabine while on is first-line patent has as designation XXXX multiple gemcitabine, resistance, for to receiving U.S. to agent may the metastatic the XXXX or which an for XXXX development. causes of therapy It gemcitabine. exist cancer advanced use and in Unfortunately, presently other chemotherapy pancreatic of gemcitabine as of non-small second-line types to is XX% are resistant cancer cancer,
gemcitabine. the regulated, normal enzyme for activation exist in dCK. activation dCK, than is more dCKX dCKX, first enzyme in gemcitabine patients than And down is activation Our resulting is The less different in cells cells. from which XXXX cancer many
Secondly, enzyme compete results reductase RRMX with cytidine killing cancer the increase in is ribonucleotide gemcitabine and RRMX up-regulated, with in nucleotide. the this an nucleotide, which then endogenous active
RRMX up-regulation the production this XXXX XXXX, RRMX cancer For of now killing actually stimulates of nucleotides. and the
demonstrated note pancreatic addition, in cancer also DNA gemcitabine-resistant efficacy following cancer affects the patients. not gemcitabine. to cell than pathway, that XXXX follow resulting of a only RNA a pharmacological different In XXXX methyltransferase, pathway same DNA has gemcitabine and of number apoptosis, It it cancer the cell but been important small in affecting is already apoptosis
slide. Next
on our mission to be Our development existing benefit/risk program treatment overall options. improve will over the based profile
means to to done targeting respond do the and identify or not respond this biomarkers activate believe molecules more of or patients few gemcitabine. which or gemcitabine. over likely patients to not XXXX this refinement for development probably to XXXX, a biological through are can We who will For be assays
in XX Assessment Over the and we move X we pancreatic to evaluate a half second the pivotal study X months, hope be to the Phase XXXX Protocol assay cancer that such biomarker the Special of XXXX. able in biomarker or XB Phase our to complete to next in initiated assay FDA trial development, XXXX then will
slide. Next
chemotherapy a profile we capecitabine, progression-free this billion chemotherapy since second or benefit/risk capecitabine the in other oral first oncology XXXXs. Xeloda, PCSXXXX, therapy, altering potentially just drug the and the of XXXX $X is combination, drugs metabolism second the the line dollar survival the XXXX by the improving a is potential results of treatment a colorectal If in the multiple market one include of making used which a the widely for of X-FU, drug cancers a decrease metastatic where or modifier capecitabine the patients, while targeted of potential side-effects, cancer. for cornerstone market billion The of of to is has market. form improve capecitabine cancer capecitabine the
information these regulatory science exists identify Using have demonstrating the improve of to related likely who future. with help most in compounds. Next this slide. Phase over to those potential XB drugs trial design XB will design present Preliminary only a capecitabine but also presently will efficacy found that Phase related from benefit trial, safety, patients the we therapy X that profile administration will the better or evidence X-FU not like also targeted for obtain adaptive XXXX Phase we X-FU treatments. the From biomarkers our to near a approach, expect an
of of X in And first XXXX. we or Over the interim months, fourth in expect our half XX the Phase define next in an to second trial to Phase XB tolerated quarter pivotal XXXX of X the or analysis complete XXXX. our XXXX, dose the maximum cohorts X our then begin
slide key these summary This presents but in in timeline for clinical of just the for slide. all already drugs our timeline months pipeline. milestones a X X slide the XX this Next next to over milestones mentioned milestones, a provides I've the format. the
we the and expect months. last accomplished we to development the over Next next expect summarizes next to accomplish first even slide over in lot a slide. We second This months. more the quarter, but in accomplish X X what
enrollment First, for interim of XXX. analysis complete patients the a of
Gastroparesis. for Second, IND in XXXXX clearance
XXXX presenting Congress we'll X August presenting Fifth, and and World that And biomarker that XB to analysis It's in at lastly, XX, are have capecitabine Phase cash Healthcare of of trial, the September with identification dose efforts XB that we the Conference the through Phase the we trial, our administered as Fall of XXX and Science of well the development hope note $XX.X tolerated with months when XA to Life be XX MedTech escalation to understanding XXXXX at Phase assays. completing of in dose the on of earnings Third initial XX X XX. first XXXX, X of a Orphan Oppenheimer Jim call of X have XXXX, - we the development XX. the as important June in cash XXXX the assays. the in everyone the Fourth, what Phase last biomarker mentioned, million Drug XXXX. XXXX I support better this we've accomplished the Cohort study. given XXXX to months as trial, XB maximum over has while the enough
to more see, we start lot we of a And interim become Processa you believe next have value as seeing months. can the As X do we the results. over also apparent And program, for my concludes closer can one Q&A. ask remarks. FDA open lines you please Operator, operator questions? I'll step to poll with to now phone for the each That the will approval.
